FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 3,721 shares of FibroGen stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $28.95, for a total transaction of $107,722.95. Following the sale, the insider now owns 221,507 shares of the company’s stock, valued at approximately $6,412,627.65. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
K Peony Yu also recently made the following trade(s):
- On Wednesday, May 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $26.38, for a total transaction of $131,900.00.
- On Tuesday, April 25th, K Peony Yu sold 5,000 shares of FibroGen stock. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00.
FibroGen, Inc (NASDAQ FGEN) traded up 1.53% on Friday, reaching $29.80. 822,104 shares of the company traded hands. The firm has a 50 day moving average of $27.85 and a 200-day moving average of $24.85. The stock’s market capitalization is $2.08 billion. FibroGen, Inc has a one year low of $14.50 and a one year high of $29.80.
FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The business had revenue of $26.89 million during the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. On average, analysts anticipate that FibroGen, Inc will post ($1.81) EPS for the current year.
Separately, Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.50.
Hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. purchased a new stake in FibroGen during the first quarter worth $111,000. Airain ltd purchased a new stake in FibroGen during the first quarter worth $236,000. Parametric Portfolio Associates LLC purchased a new stake in FibroGen during the first quarter worth $249,000. UBS Asset Management Americas Inc. purchased a new stake in FibroGen during the first quarter worth $288,000. Finally, Clinton Group Inc. purchased a new stake in FibroGen during the first quarter worth $297,000. 44.08% of the stock is owned by institutional investors and hedge funds.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229034/fibrogen-inc-fgen-insider-k-peony-yu-sells-3721-shares.html
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.